A very special patient of mine, Kyle, passed away from a brainstem glioma at age 7. I founded Presage because the frequency with which we, as oncologists, unknowingly prescribe therapies to which our patients’ tumors are already resistant is unacceptable. We need better approaches to identify drug combinations that will provide benefit and improve patient survival. Presage is addressing this need in three important ways: by partnering with pharmaceutical companies to identify effective drug combinations, partnering with academic researchers to identify preclinical therapeutics that are “diamonds in the rough” and partnering with oncologists and their patients to prioritize drugs.
James Olson, M.D., Ph.D